Laekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial

MT Newswires Live

04/15

Laekna (HKG:2105) said its LAE002 oral drug met the primary endpoint of progression-free survival in a phase 3 clinical trial, according to a Hong Kong bourse filing Wednesday.

Results from the FFIRM-205 study showed that a combination of LAE002 and fulvestrant achieved a progression-free survival of 7.6 months in subjects with breast cancer, compared with two months for fulvestrant alone.

The firm has a China licensing agreement with Qilu Pharmaceutical for LAE002 under which it is eligible to receive up to 2.05 billion yuan in total upfront and milestone payments.

The firm said it will submit a new drug application for LAE002 in China in the "near term."

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2627477078"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627477078\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627477078?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 12:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627477078","market":"sh","top_or_hot":-1,"title":"Laekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial","media":"MT Newswires Live","content":"<html><body><p> Laekna (HKG:2105) said its LAE002 oral drug met the primary endpoint of progression-free survival in a phase 3 clinical trial, according to a Hong Kong bourse filing Wednesday.</p><p>Results from the FFIRM-205 study showed that a combination of LAE002 and fulvestrant achieved a progression-free survival of 7.6 months in subjects with breast cancer, compared with two months for fulvestrant alone.</p><p>The firm has a China licensing agreement with Qilu Pharmaceutical for LAE002 under which it is eligible to receive up to 2.05 billion yuan in total upfront and milestone payments.</p><p>The firm said it will submit a new drug application for LAE002 in China in the \"near term.\"</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Laekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLaekna Says Cancer Drug Meets Progression-free Survival Goal in Phase 3 Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-15 12:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Laekna (HKG:2105) said its LAE002 oral drug met the primary endpoint of progression-free survival in a phase 3 clinical trial, according to a Hong Kong bourse filing Wednesday.</p><p>Results from the FFIRM-205 study showed that a combination of LAE002 and fulvestrant achieved a progression-free survival of 7.6 months in subjects with breast cancer, compared with two months for fulvestrant alone.</p><p>The firm has a China licensing agreement with Qilu Pharmaceutical for LAE002 under which it is eligible to receive up to 2.05 billion yuan in total upfront and milestone payments.</p><p>The firm said it will submit a new drug application for LAE002 in China in the \"near term.\"</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02105","symbol_name":"來凱醫藥-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2627477078","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627477078","pubTimestamp":1776227646,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Laekna  said its LAE002 oral drug met the primary endpoint of progression-free survival in a phase 3 clinical trial, according to a Hong Kong bourse filing Wednesday.Results from the FFIRM-205 study showed that a combination of LAE002 and fulvestrant achieved a progression-free survival of 7.6 months in subjects with breast cancer, compared with two months for fulvestrant alone.The firm has a China licensing agreement with Qilu Pharmaceutical for LAE002 under which it is eligible to receive up to 2.05 billion yuan in total upfront and milestone payments.The firm said it will submit a new drug application for LAE002 in China in the \"near term.\"","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02105":"来凯医药-B","BK1161":"生物科技"},"translate_title":"Laekna称癌症药物在3期试验中达到无进展生存期目标","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1},"content_text":"Laekna (HKG:2105) said its LAE002 oral drug met the primary endpoint of progression-free survival in a phase 3 clinical trial, according to a Hong Kong bourse filing Wednesday.Results from the FFIRM-205 study showed that a combination of LAE002 and fulvestrant achieved a progression-free survival of 7.6 months in subjects with breast cancer, compared with two months for fulvestrant alone.The firm has a China licensing agreement with Qilu Pharmaceutical for LAE002 under which it is eligible to receive up to 2.05 billion yuan in total upfront and milestone payments.The firm said it will submit a new drug application for LAE002 in China in the \"near term.\"","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}